Search

Your search keyword '"van den Eertwegh, AJM"' showing total 16 results
Start Over Author "van den Eertwegh, AJM" Database OAIster
16 results on '"van den Eertwegh, AJM"'

1. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma:the multicentre prospective Safe Stop trial

Author

Mulder, Evalyn, de Joode, Karlijn, Litière, S., ten Tije, AJ, Suijkerbuijk, KPM, Boers-Sonderen, M. J., Hospers, GAP, de Groot, JWB, van den Eertwegh, AJM (Fons), Aarts, MJB, Piersma, D., van Rijn, RS, Kapiteijn, E, Vreugdenhil, G, van den Berkmortel, FWPJ, Oomen-de Hoop, E, Franken, Margreet, Ryll, B., Rutkowski, P, Sleijfer, Stefan, Haanen, JBAG, van der Veldt, Astrid, Mulder, Evalyn, de Joode, Karlijn, Litière, S., ten Tije, AJ, Suijkerbuijk, KPM, Boers-Sonderen, M. J., Hospers, GAP, de Groot, JWB, van den Eertwegh, AJM (Fons), Aarts, MJB, Piersma, D., van Rijn, RS, Kapiteijn, E, Vreugdenhil, G, van den Berkmortel, FWPJ, Oomen-de Hoop, E, Franken, Margreet, Ryll, B., Rutkowski, P, Sleijfer, Stefan, Haanen, JBAG, and van der Veldt, Astrid

Abstract

Background: The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients with advanced melanoma. However, the long treatment duration (i.e. two years or longer) has a high impact on patients and healthcare systems in terms of (severe) toxicity, health-related quality of life (HRQoL), resource use, and healthcare costs. While durable tumour responses have been observed and PD-1 blockade is discontinued on an individual basis, no consensus has been reached on the optimal treatment duration. The objective of the Safe Stop trial is to evaluate whether early discontinuation of first-line PD-1 blockade is safe in patients with advanced and metastatic melanoma who achieve a radiological response. Methods: The Safe Stop trial is a nationwide, multicentre, prospective, single-arm, interventional study in the Netherlands. A total of 200 patients with advanced and metastatic cutaneous melanoma and a confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumours (RECIST) v1.1 will be included to early discontinue first-line monotherapy with nivolumab or pembrolizumab. The primary objective is the rate of ongoing responses at 24 months after discontinuation of PD-1 blockade. Secondary objectives include best overall and duration of response, need and outcome of rechallenge with PD-1 blockade, and changes in (serious) adverse events and HRQoL. The impact of treatment discontinuation on healthcare resource use, productivity losses, and hours of informal care will also be assessed. Results will be compared to those from patients with CR or PR who completed 24 months of treatment with PD-1 blockade and had an ongoing response at treatment discontinuation. It is hypothesised that it is safe to early stop first-line nivolumab or pembrolizumab at confirmed tumour response while improving HRQoL and reducing costs.

Published
2021

2. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, J, Wouters, M, Hilarius, DL, Haanen, JB, Blank, CU, Aarts, MJB, van den Berkmortel, F, de Groot, JWB, Hospers, GAP, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, Blokx, WAM, ten Tije, BJJ, van der Veldt, Astrid, Vreugdenhil, A, Boers-Sonderen, MJ, Van den Eertwegh, AJM, van Breeschoten, J, Wouters, M, Hilarius, DL, Haanen, JB, Blank, CU, Aarts, MJB, van den Berkmortel, F, de Groot, JWB, Hospers, GAP, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, Blokx, WAM, ten Tije, BJJ, van der Veldt, Astrid, Vreugdenhil, A, Boers-Sonderen, MJ, and Van den Eertwegh, AJM

Abstract

Background: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAFV600-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced BRAFV600-mutant melanoma patients. Methods: We selected patients diagnosed between 2014 and 2017 with advanced melanoma and a known BRAFV600-mutation treated with first-line BRAF/MEK inhibitors or anti-PD-1 antibodies, registered in the Dutch Melanoma Treatment Registry. Patients were matched based on their propensity scores using the nearest neighbour and the optimal matching method. Results: Between 2014 and 2017, a total of 330 and 254 advanced melanoma patients received BRAF/MEK inhibitors and anti-PD-1 monotherapy as first-line systemic therapy. In the matched cohort, patients receiving anti-PD-1 antibodies as a first-line treatment had a higher median and 2-year overall survival compared to patients treated with first-line BRAF/MEK inhibitors, 42.3 months (95% CI: 37.3-NE) vs. 19.8 months (95% CI: 16.7–24.3) and 65.4% (95% CI: 58.1–73.6) vs. 41.7% (95% CI: 34.2–51.0). Conclusions: Our data suggest that in the matched BRAFV600-mutant advanced melanoma patients, anti-PD-1 monotherapy is the preferred first-line treatment in patients with relatively favourable patient and tumour characteristics.

Published
2021

3. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial

Author

Eggermont, AMM, Kicinski, M, Blank, CU, Mandala, M, Long, GV, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, MS, Sandhu, S, Larkin, J, Puig, S, Ascierto, PA, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, AM, van den Eertwegh, AJM, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, PC, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C, Suciu, S, Eggermont, AMM, Kicinski, M, Blank, CU, Mandala, M, Long, GV, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, MS, Sandhu, S, Larkin, J, Puig, S, Ascierto, PA, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, AM, van den Eertwegh, AJM, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, PC, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C, and Suciu, S

Abstract

IMPORTANCE: Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown. OBJECTIVE: To investigate the association between irAEs and recurrence-free survival (RFS) in the double-blind EORTC 1325/KEYNOTE-054 clinical trial comparing pembrolizumab therapy and placebo for the treatment of patients with high-risk stage III melanoma. DESIGN, SETTING, AND PARTICIPANTS: A total of 1019 adults with stage III melanoma were randomly assigned on a 1:1 ratio to receive treatment with pembrolizumab therapy or placebo. Eligible patients were adults 18 years and older with complete resection of cutaneous melanoma metastatic to lymph nodes, classified with stage IIIA (at least 1 micrometastasis measuring >1 mm in greatest diameter), IIIB, or IIIC (without in-transit metastasis) cancer. Patients were randomized from August 26, 2015, to November 14, 2016. The clinical cutoff for the data set was October 2, 2017. Analyses were then performed on the database, which was locked on November 28, 2017. INTERVENTIONS: Participants were scheduled to receive 200 mg of pembrolizumab or placebo every 3 weeks for a total of 18 doses for approximately 1 year or until disease recurrence, unacceptable toxic effects, major protocol violation, or withdrawal of consent. MAIN OUTCOMES AND MEASURES: The association between irAEs and RFS was estimated using a Cox model adjusted for sex, age, and AJCC-7 stage, with a time-varying covariate that had a value of 0 before irAE onset and 1 after irAE onset. RESULTS: Of 1011 patients who began treatment with pembrolizumab therapy or placebo, 622 (61.5%) were men and 389 (38.5%) were women; 386 patients (38.2%) were aged 50 to 64 years, 377 (37.3%) were younger than 50 years, and 248 (24.5%) were 65 years and older. Consistent with the reported main analysis in the intent-to-treat population, RFS was longer in the pembrolizumab arm compared with the placebo arm (hazard ratio [HR], 0.56

Published
2020

4. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Author

Eggermont, AMM, Blank, CU, Mandala, M, Long, GV, Atkinson, VG, Dalle, S, Haydon, AM, Meshcheryakov, A, Khattak, A, Carlino, MS, Sandhu, S, Larkin, J, Puig, S, Ascierto, PA, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, AM, van den Eertwegh, AJM, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, PC, van Akkooi, ACJ, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S, Robert, C, Eggermont, AMM, Blank, CU, Mandala, M, Long, GV, Atkinson, VG, Dalle, S, Haydon, AM, Meshcheryakov, A, Khattak, A, Carlino, MS, Sandhu, S, Larkin, J, Puig, S, Ascierto, PA, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, AM, van den Eertwegh, AJM, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, PC, van Akkooi, ACJ, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S, and Robert, C

Abstract

PURPOSE: We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. On the basis of 351 recurrence-free survival (RFS) events at a 1.25-year median follow-up, pembrolizumab prolonged RFS (hazard ratio [HR], 0.57; P < .0001) compared with placebo. This led to the approval of pembrolizumab adjuvant treatment by the European Medicines Agency and US Food and Drug Administration. Here, we report an updated RFS analysis at the 3.05-year median follow-up. PATIENTS AND METHODS: A total of 1,019 patients with complete lymph node dissection of American Joint Committee on Cancer Staging Manual (seventh edition; AJCC-7), stage IIIA (at least one lymph node metastasis > 1 mm), IIIB, or IIIC (without in-transit metastasis) cutaneous melanoma were randomly assigned to receive pembrolizumab at a flat dose of 200 mg (n = 514) or placebo (n = 505) every 3 weeks for 1 year or until disease recurrence or unacceptable toxicity. The two coprimary end points were RFS in the overall population and in those with programmed death-ligand 1 (PD-L1)-positive tumors. RESULTS: Pembrolizumab (190 RFS events) compared with placebo (283 RFS events) resulted in prolonged RFS in the overall population (3-year RFS rate, 63.7% v 44.1% for pembrolizumab v placebo, respectively; HR, 0.56; 95% CI, 0.47 to 0.68) and in the PD-L1-positive tumor subgroup (HR, 0.57; 99% CI, 0.43 to 0.74). The impact of pembrolizumab on RFS was similar in subgroups, in particular according to AJCC-7 and AJCC-8 staging, and BRAF mutation status (HR, 0.51 [99% CI, 0.36 to 0.73] v 0.66 [99% CI, 0.46 to 0.95] for V600E/K v wild type). CONCLUSION: In resected high-risk stage III melanoma, pembrolizumab adjuvant therapy provided a sustained and clinically meaningful improvement in RFS at 3-year median follow-up. This improvement was consistent across subgroups.

Published
2020

5. Age does matter in adolescents and young adults versus older adults with advanced melanoma; a national cohort study comparing tumor characteristics, treatment pattern, toxicity and response

Author

van der Kooij, MK, Wetzels, MJAL, Aarts, MJB, van den Berkmortel, FWP, Blank, CU, Boers-Sonderen, MJ, Dierselhuis, MP, Groot, JWH, Hospers, GA, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, van der Veldt, Astrid, Vreugdenhil, G, Wouters, M, Haanen, JB, Van den Eertwegh, AJM, Bastiaannet, E, Kapiteijn, E, van der Kooij, MK, Wetzels, MJAL, Aarts, MJB, van den Berkmortel, FWP, Blank, CU, Boers-Sonderen, MJ, Dierselhuis, MP, Groot, JWH, Hospers, GA, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, van der Veldt, Astrid, Vreugdenhil, G, Wouters, M, Haanen, JB, Van den Eertwegh, AJM, Bastiaannet, E, and Kapiteijn, E

Published
2020

6. Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands

Author

Kuppen, Malou, Westgeest, HM, Van den Eertwegh, AJM, Coenen, J, van Moorselaar, RJA, Berg, P, Geenen, MM, Mehra, N, Hendriks, MP, Lampe, MI, van de Luijtgaarden, ACM, Peters, FPJ, Roeleveld, TA, Smilde, TJ, de Wit, Ronald, van Oort, IM, Gerritsen, WR, Uyl - de Groot, Carin, Kuppen, Malou, Westgeest, HM, Van den Eertwegh, AJM, Coenen, J, van Moorselaar, RJA, Berg, P, Geenen, MM, Mehra, N, Hendriks, MP, Lampe, MI, van de Luijtgaarden, ACM, Peters, FPJ, Roeleveld, TA, Smilde, TJ, de Wit, Ronald, van Oort, IM, Gerritsen, WR, and Uyl - de Groot, Carin

Published
2020

7. Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

Author

Leeneman, Brenda, Uyl - de Groot, Carin, Aarts, MJB, Akkooi, ACJ, van den Berkmortel, F, Van den Eertwegh, AJM, de Groot, JW, Herbschleb, KH, van der Hoeven, JJ, Hospers, GA, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, van der Veldt, Astrid, Vreugdenhil, G, Wouters, M, Haanen, J, Franken, Margreet, Leeneman, Brenda, Uyl - de Groot, Carin, Aarts, MJB, Akkooi, ACJ, van den Berkmortel, F, Van den Eertwegh, AJM, de Groot, JW, Herbschleb, KH, van der Hoeven, JJ, Hospers, GA, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, van der Veldt, Astrid, Vreugdenhil, G, Wouters, M, Haanen, J, and Franken, Margreet

Published
2020

8. Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy

Author

Blankenstein, SA, Aarts, MJB, van den Berkmortel, F, Boers-Sonderen, MJ, Van den Eertwegh, AJM, Franken, Margreet, Groot, J, Haanen, J, Hospers, GA, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, van der Veldt, Astrid, Vreugdenhil, G, Wouters, M, Akkooi, ACJ, Blankenstein, SA, Aarts, MJB, van den Berkmortel, F, Boers-Sonderen, MJ, Van den Eertwegh, AJM, Franken, Margreet, Groot, J, Haanen, J, Hospers, GA, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, van der Veldt, Astrid, Vreugdenhil, G, Wouters, M, and Akkooi, ACJ

Published
2020

9. Real-world outcomes of advanced melanoma patients not represented in phase III trials

Author

van Zeijl, MCT, Ismail, RK, de Wreede, L C, Van den Eertwegh, AJM, Boer, A, Dartel, M, Hilarius, DL, Aarts, MJB, van den Berkmortel, FWP, Boers-Sonderen, MJ, de Groot, J, Hospers, GA, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, Tije, AJ, van der Veldt, Astrid, Vreugdenhil, G, Haanen, JB, Wouters, MWJM (Michel), van Zeijl, MCT, Ismail, RK, de Wreede, L C, Van den Eertwegh, AJM, Boer, A, Dartel, M, Hilarius, DL, Aarts, MJB, van den Berkmortel, FWP, Boers-Sonderen, MJ, de Groot, J, Hospers, GA, Kapiteijn, E, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, Tije, AJ, van der Veldt, Astrid, Vreugdenhil, G, Haanen, JB, and Wouters, MWJM (Michel)

Published
2020

10. Lower risk of severe checkpoint inhibitor toxicity in more advanced disease

Author

Verheijden, RJ, May, AM, Blank, CU, Veldt, Astrid, Boers-Sonderen, MJ, Aarts, MJB, van den Berkmortel, F, Van den Eertwegh, AJM, Groot, Jan Willem, van der Hoeven, JJ, Hospers, GA, Piersma, Djura, van Rijn, RS, ten Tije, AJ, Vreugdenhil, G, van Zeijl, MCT, Wouters, Michel, Haanen, J, Kapiteijn, E, Suijkerbuijk, KPM, Verheijden, RJ, May, AM, Blank, CU, Veldt, Astrid, Boers-Sonderen, MJ, Aarts, MJB, van den Berkmortel, F, Van den Eertwegh, AJM, Groot, Jan Willem, van der Hoeven, JJ, Hospers, GA, Piersma, Djura, van Rijn, RS, ten Tije, AJ, Vreugdenhil, G, van Zeijl, MCT, Wouters, Michel, Haanen, J, Kapiteijn, E, and Suijkerbuijk, KPM

Published
2020

11. Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands

Author

Westgeest, Hans, Kuppen, Malou, Van den Eertwegh, AJM, de Wit, Ronald, Coenen, J, van den Berg, HP, Mehra, N, van Oort, IM, Fossion, L, Hendriks, MP, Bloemendal, HJ, van de Luijtgaarden, ACM, Huinink, DT, van den Bergh, ACM, Bosch, JG, Polee, MB, Weijl, N, Bergman, AM, Uyl - de Groot, Carin, Gerritsen, WR, Westgeest, Hans, Kuppen, Malou, Van den Eertwegh, AJM, de Wit, Ronald, Coenen, J, van den Berg, HP, Mehra, N, van Oort, IM, Fossion, L, Hendriks, MP, Bloemendal, HJ, van de Luijtgaarden, ACM, Huinink, DT, van den Bergh, ACM, Bosch, JG, Polee, MB, Weijl, N, Bergman, AM, Uyl - de Groot, Carin, and Gerritsen, WR

Published
2019

12. Re: Risk of solid cancer after treatment of testicular germ cell cancer in the platinum era

Author

de Groot, HJ, Lubberts, S, de Wit, Ronald, Witjes, JA, Kerst, JM, de Jong, IJ, Groenewegen, G, Van den Eertwegh, AJM, Poortmans, PM, Klümpen, HJ, van den Berg, HA, Smilde, TJ, Vanneste, BGL, Aarts, MJB, Incrocci, Luca, van den Bergh, ACM, Jozwiak, K, van den Belt-Dusebout, AW, Horenblas, S, Gietema, JA, van Leeuwen, FE, Schaapveld, M, de Groot, HJ, Lubberts, S, de Wit, Ronald, Witjes, JA, Kerst, JM, de Jong, IJ, Groenewegen, G, Van den Eertwegh, AJM, Poortmans, PM, Klümpen, HJ, van den Berg, HA, Smilde, TJ, Vanneste, BGL, Aarts, MJB, Incrocci, Luca, van den Bergh, ACM, Jozwiak, K, van den Belt-Dusebout, AW, Horenblas, S, Gietema, JA, van Leeuwen, FE, and Schaapveld, M

Published
2019

13. Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry

Author

Jochems, A, van der Kooij, MK, Fiocco, M, Schouwenburg, MG, Aarts, MJB, Akkooi, ACJ, van den Berkmortel, F, Blank, CU, Van den Eertwegh, AJM, Franken, Margreet, de Groot, JB, Haanen, J, Hospers, GA, Koornstra, RH, Kruit, Wim, Louwman, M, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, Vreugdenhil, G, Wouters, M, van Zeijl, MCT, van der Hoeven, KJM, Kapiteijn, E, Jochems, A, van der Kooij, MK, Fiocco, M, Schouwenburg, MG, Aarts, MJB, Akkooi, ACJ, van den Berkmortel, F, Blank, CU, Van den Eertwegh, AJM, Franken, Margreet, de Groot, JB, Haanen, J, Hospers, GA, Koornstra, RH, Kruit, Wim, Louwman, M, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, Vreugdenhil, G, Wouters, M, van Zeijl, MCT, van der Hoeven, KJM, and Kapiteijn, E

Published
2019

14. Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands

Author

Franken, Margreet, Leeneman, Brenda, Jochems, A, Schouwenburg, MG, Aarts, MJB, Akkooi, ACJ, van den Berkmortel, F, Van den Eertwegh, AJM, de Groot, JWB, van der Hoeven, JJM, Hospers, GAP, Kapiteijn, E, Koornstra, RH, Kruit, Wim, Louwman, MW, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, Vreugdenhil, G, Wouters, MWJM, Zeijl, M, Haanen, JBAG, Uyl - de Groot, Carin, Franken, Margreet, Leeneman, Brenda, Jochems, A, Schouwenburg, MG, Aarts, MJB, Akkooi, ACJ, van den Berkmortel, F, Van den Eertwegh, AJM, de Groot, JWB, van der Hoeven, JJM, Hospers, GAP, Kapiteijn, E, Koornstra, RH, Kruit, Wim, Louwman, MW, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, Vreugdenhil, G, Wouters, MWJM, Zeijl, M, Haanen, JBAG, and Uyl - de Groot, Carin

Published
2018

15. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands

Author

Jochems, A, Leeneman, Brenda, Franken, Margreet, Schouwenburg, MG, Aarts, MJB, Akkooi, Alexander, van den Berkmortel, F, Van den Eertwegh, AJM, Groenewegen, G, de Groot, JWB, Haanen, JBAG, Hospers, GAP, Kapiteijn, E, Koornstra, RH, Kruit, Wim, Louwman, MW, Piersma, D, van Rijn, RS, ten Tije, AJ, Vreugdenhil, G, Wouters, MWJM, Uyl - de Groot, Carin, van der Hoeven, JJM, Jochems, A, Leeneman, Brenda, Franken, Margreet, Schouwenburg, MG, Aarts, MJB, Akkooi, Alexander, van den Berkmortel, F, Van den Eertwegh, AJM, Groenewegen, G, de Groot, JWB, Haanen, JBAG, Hospers, GAP, Kapiteijn, E, Koornstra, RH, Kruit, Wim, Louwman, MW, Piersma, D, van Rijn, RS, ten Tije, AJ, Vreugdenhil, G, Wouters, MWJM, Uyl - de Groot, Carin, and van der Hoeven, JJM

Published
2018

16. Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry

Author

Westgeest, Hans, Uyl - de Groot, Carin, van Moorselaar, RJA, de Wit, Ronald, van den Bergh, ACM, Coenen, JLLM, Beerlage, HP, Hendriks, MP, Bos, MMEM, van den Berg, P, van de Wouw, AJ, Spermon, T, Boerma, MO, Geenen, MM, Tick, LW, Polee, MB, Bloemendal, HJ, Cordia, I, Peters, FPJ, de Vos, AI, van den van den Bosch, J, Van den Eertwegh, AJM, Gerritsen, WR, Westgeest, Hans, Uyl - de Groot, Carin, van Moorselaar, RJA, de Wit, Ronald, van den Bergh, ACM, Coenen, JLLM, Beerlage, HP, Hendriks, MP, Bos, MMEM, van den Berg, P, van de Wouw, AJ, Spermon, T, Boerma, MO, Geenen, MM, Tick, LW, Polee, MB, Bloemendal, HJ, Cordia, I, Peters, FPJ, de Vos, AI, van den van den Bosch, J, Van den Eertwegh, AJM, and Gerritsen, WR

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results